Renovis, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for neurological diseases and disorders. Its advanced product candidate, NXY-059, is in Phase III clinical trials for acute ischemic stroke with the company’s exclusive licensee, AstraZeneca AB. NXY-059 is being studied as a neuroprotectant in clinical trials based on effects seen in experimental models of acute ischemic stroke. In addition to proprietary research programs in the areas of cytoprotection, pain, and inflammation, Renovis has a worldwide collaboration and license agreement with Pfizer, Inc. to research, develop, and commercialize small molecule VR1 antagonists; and a research...